353 related articles for article (PubMed ID: 12783417)
1. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
Barkhof F; Rocca M; Francis G; Van Waesberghe JH; Uitdehaag BM; Hommes OR; Hartung HP; Durelli L; Edan G; Fernández O; Seeldrayers P; Sørensen P; Margrie S; Rovaris M; Comi G; Filippi M;
Ann Neurol; 2003 Jun; 53(6):718-24. PubMed ID: 12783417
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
[TBL] [Abstract][Full Text] [Related]
3. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
O'Connor P; Kinkel RP; Kremenchutzky M
Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
[TBL] [Abstract][Full Text] [Related]
5. Defining interferon beta response status in multiple sclerosis patients.
Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
[TBL] [Abstract][Full Text] [Related]
6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
7. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients.
Lebrun C; Bensa C; Debouverie M; Wiertlevski S; Brassat D; de Seze J; Rumbach L; Pelletier J; Labauge P; Brochet B; Tourbah A; Clavelou P;
Arch Neurol; 2009 Jul; 66(7):841-6. PubMed ID: 19597085
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
[TBL] [Abstract][Full Text] [Related]
9. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis.
Rovira A; Swanton J; Tintoré M; Huerga E; Barkhof F; Filippi M; Frederiksen JL; Langkilde A; Miszkiel K; Polman C; Rovaris M; Sastre-Garriga J; Miller D; Montalban X
Arch Neurol; 2009 May; 66(5):587-92. PubMed ID: 19433658
[TBL] [Abstract][Full Text] [Related]
10. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis.
Swanton JK; Fernando KT; Dalton CM; Miszkiel KA; Altmann DR; Plant GT; Thompson AJ; Miller DH
Mult Scler; 2010 Feb; 16(2):156-65. PubMed ID: 20086028
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis.
Villar LM; García-Barragán N; Sádaba MC; Espiño M; Gómez-Rial J; Martínez-San Millán J; González-Porqué P; Alvarez-Cermeño JC
J Neurol Sci; 2008 Mar; 266(1-2):34-7. PubMed ID: 17884100
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y
Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
[TBL] [Abstract][Full Text] [Related]
14. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
Comi G
Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
[TBL] [Abstract][Full Text] [Related]
15. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
Waubant E; Sloan R; Andersson PB; Goodkin D
Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
[TBL] [Abstract][Full Text] [Related]
16. MRI of multiple sclerosis in Thai patients.
Chawalparit O; Prayoonwiwat N
J Med Assoc Thai; 2006 Apr; 89(4):422-7. PubMed ID: 16696384
[TBL] [Abstract][Full Text] [Related]
17. Baseline MRI predicts future attacks and disability in clinically isolated syndromes.
Tintoré M; Rovira A; Río J; Nos C; Grivé E; Téllez N; Pelayo R; Comabella M; Sastre-Garriga J; Montalban X
Neurology; 2006 Sep; 67(6):968-72. PubMed ID: 17000962
[TBL] [Abstract][Full Text] [Related]
18. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.
Moraal B; van den Elskamp IJ; Knol DL; Uitdehaag BM; Geurts JJ; Vrenken H; Pouwels PJ; van Schijndel RA; Meier DS; Guttmann CR; Barkhof F
Ann Neurol; 2010 May; 67(5):667-75. PubMed ID: 20437564
[TBL] [Abstract][Full Text] [Related]
19. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
[TBL] [Abstract][Full Text] [Related]
20. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ;
Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
